Skip to main content

The Editorial Board recommends

EASD 2019 clinical trial recommendation

The DEFINE-HF trial

Wednesday, September 18, 13:15–14:15. Vilanova Hall, Fira Barcelona Gran Via, Spain 

TRIAL RESULTS PUBLISHED | Read the full story

A 12-week randomized, double-blind, placebo-controlled trial to evaluate the effects of once-daily dapagliflozin 10 mg on heart failure disease-specific biomarkers (BNP and NTproBNP), symptoms, health status, and quality of life in patients with chronic heart failure plus reduced systolic function.



Whilst we are waiting for the results of big outcome trials with SGLT2 inhibitors in people with heart failure with and without diabetes, this smaller but important trial may give some useful information about mechanisms and other potential benefits.


John Wilding, Professor of Medicine, UK

EASD 2019 clinical trial recommendation

Imeglimin: A first-in-class oral medication with a unique mechanism of action targeting mitochondrial bioenergetics

Wednesday, September 18, 12:00–13:00. Ochoa Hall, Fira Barcelona Gran Via, Spain

TRIAL RESULTS PUBLISHED | Read the full story

A novel agent for type 2 diabetes targeting mitochondrial dysfunction – will phase 3 clinical trial data support the theoretical promise of this approach?


John Wilding, Professor of Medicine, UK

EASD 2019 clinical trial recommendation

Results from the anti-CD3 mAb (teplizumab) prevention trial

Tuesday, September 17, 13:15–14:15. Vilanova Hall, Fira Barcelona Gran Via, Spain

CLINICAL TRIAL OVERVIEW | Learn more about the anti-CD3 mAb diabetes prevention trial here

A potentially interesting look at long-term data from trials of this potential immunotherapy for type 1 diabetes.


John Wilding, Professor of Medicine, UK

EASD 2019 session recommendation

Why is paediatric type 2 diabetes a more aggressive disease?

Wednesday, September 18, 08:30–10:00. Vilanova Hall, Fira Barcelona Gran Via, Spain

EASD 2019 SESSION OVERVIEW | Learn more about this session here 


Type 2 diabetes accounts for an increasing proportion of people with diabetes in childhood and adolescence, and outcomes are very poor. Why is this and what can be done?


John Wilding, Professor of Medicine, UK

EASD 2019 session recommendation

The St Vincent Declaration: 30 years on

Wednesday, September 18, 12:00–13:00. Vilanova Hall, Fira Barcelona Gran Via, Spain

EASD 2019 SESSION OVERVIEW | Learn more about this session here


How much has been achieved since this famous declaration, which set clear goals for diabetes outcomes? This session should provide a good overview.


John Wilding, Professor of Medicine, UK

EASD 2019 session recommendation

EASD/EASL symposium: Is NAFLD a risk for health in the context of diabetes?

Friday, September 20, 08:30–09:30. Joslin Hall, Fira Barcelona Gran Via, Spain

EASD 2019 SESSION OVERVIEW | Learn more about the EASD/EASL symposium here

Non-alcoholic fatty liver disease (NAFLD) is increasingly common in diabetes; this symposium should help to guide clinicians to use the right approaches for diagnosis and management.


John Wilding, Professor of Medicine, UK

EASD 2019 sessison recommendation

Personalising the screening for sight threatening diabetic retinopathy

Friday, September 20, 12:15–13:45. Joslin Hall, Fira Barcelona Gran Via, Spain

EASD 2019 SESSION OVERVIEW | Learn more about this session here


Can risk-based and personalized screening approaches help to optimize retinopathy screening in diabetes?


John Wilding, Professor of Medicine, UK

EASD 2019 clinical study recommendation

The Beijing Community Diabetes Study (BCDS)

Tuesday, September 17, 13:15–14:15. Joslin Hall, Fira Barcelona Gran Via, Spain

TRIAL RESULTS PUBLISHED | Read the full story

This study presents health services research on a large scale – will we gain any new insight into improving glucose control?


John Wilding, Professor of Medicine, UK

EASD 2019 clinical trial recommendation

Effect of GABA with GAD on the progression of type 1 diabetes mellitus in children

Tuesday, September 17, 12:00–13:00. Vilanova Hall, Fira Barcelona Gran Via, Spain

TRIAL RESULTS PUBLISHED | Read the full story


GABA has been shown in vitro to promote conversion of alpha cells to beta cells. Will GABA, given as a food supplement to people with C-Peptide negative type 1 diabetes, help restore beta-cell function? 


John Wilding, Professor of Medicine, UK